Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 387 articles:
HTML format
Text format



Single Articles


    April 2017
  1. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed     Text format    


    March 2017
  2. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    PubMed     Text format     Abstract available


  3. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    PubMed     Text format     Abstract available


  4. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    PubMed     Text format     Abstract available


  5. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    PubMed     Text format     Abstract available


  6. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    PubMed     Text format     Abstract available


  7. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    PubMed     Text format     Abstract available


    February 2017
  8. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    PubMed     Text format    


  9. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    PubMed     Text format     Abstract available


  10. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    PubMed     Text format     Abstract available


  11. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.
    PubMed     Text format     Abstract available


  12. ROSS J, Braswell KV, da Silva LM, Mujica F, et al
    Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30146.
    PubMed     Text format     Abstract available


  13. BURGHAUS S, Fasching PA, Haberle L, Rubner M, et al
    Genetic risk factors for ovarian cancer and their role for endometriosis risk.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30143.
    PubMed     Text format     Abstract available


  14. KOHLER RS, Kettelhack H, Knipprath-Meszaros AM, Fedier A, et al
    MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30128.
    PubMed     Text format     Abstract available


  15. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30132.
    PubMed     Text format     Abstract available


  16. SEAGLE BL, Shahabi S
    Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30125.
    PubMed     Text format     Abstract available


  17. MAI PL, Piedmonte M, Han PK, Moser RP, et al
    Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30119.
    PubMed     Text format     Abstract available


  18. KENTWELL M, Dow E, Antill Y, Wrede CD, et al
    Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Gynecol Oncol. 2017 Feb 3. pii: S0090-8258(17)30074.
    PubMed     Text format     Abstract available


  19. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Corrigendum to 'Equivalency challenge: evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Gynecol Oncol. 2017;144:448.
    PubMed     Text format    


  20. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed     Text format    


  21. COHN DE, Backes FJ, Wallbillich JJ, Bixel K, et al
    Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30067.
    PubMed     Text format     Abstract available


  22. EOH KJ, Park JS, Park HS, Lee ST, et al
    BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30070.
    PubMed     Text format     Abstract available


    January 2017
  23. WALLACE S, Kumar A, Mc Gree M, Weaver A, et al
    Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Gynecol Oncol. 2017 Jan 31. pii: S0090-8258(17)30073.
    PubMed     Text format     Abstract available


  24. CHANAKIRA A, Westmark PR, Ong IM, Sheehan JP, et al
    Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Gynecol Oncol. 2017 Jan 29. pii: S0090-8258(17)30066.
    PubMed     Text format     Abstract available


  25. ALETTI GD, Garbi A, Messori P, Achilarre MT, et al
    Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.
    Gynecol Oncol. 2017 Jan 20. pii: S0090-8258(17)30061.
    PubMed     Text format     Abstract available


  26. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Gynecol Oncol. 2017 Jan 19. pii: S0090-8258(17)30059.
    PubMed     Text format     Abstract available


  27. LIAO JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, et al
    Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046.
    PubMed     Text format     Abstract available


  28. GILLEN J, Gunderson C, Greenwade M, Rowland M, et al
    Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
    Gynecol Oncol. 2017 Jan 10. pii: S0090-8258(16)31687.
    PubMed     Text format     Abstract available


  29. ISLAM MM, Banerjee T, Packard CZ, Kotian S, et al
    HDAC10 as a potential therapeutic target in ovarian cancer.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(17)30047.
    PubMed     Text format     Abstract available


  30. TOZZI R, Hardern K, Gubbala K, Garruto Campanile R, et al
    En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(16)31683.
    PubMed     Text format     Abstract available


  31. RYAN NA, Evans DG, Green K, Crosbie EJ, et al
    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(17)30042.
    PubMed     Text format     Abstract available


  32. DIZON DS
    Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31684.
    PubMed     Text format    


  33. SPREAFICO A, Oza AM, Clarke BA, Mackay HJ, et al
    Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620.
    PubMed     Text format     Abstract available


  34. BERGAMINI A, Pisano C, Di Napoli M, Arenare L, et al
    Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecol Oncol. 2017;144:72-76.
    PubMed     Text format     Abstract available


    December 2016
  35. KESSOUS R, Laskov I, Abitbol J, Bitharas J, et al
    Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2016 Dec 29. pii: S0090-8258(16)31679.
    PubMed     Text format     Abstract available


  36. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed     Text format    


  37. DOLL KM, Pinheiro LC, Reeve BB
    Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31623.
    PubMed     Text format     Abstract available


  38. RUBERG JL, Helm CW, Felleman BI, Helm JE, et al
    Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.
    Gynecol Oncol. 2016 Dec 13. pii: S0090-8258(16)31616.
    PubMed     Text format     Abstract available


  39. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31497.
    PubMed     Text format     Abstract available


  40. MUSA F, Pothuri B, Blank SV, Ling HT, et al
    Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31612.
    PubMed     Text format     Abstract available


  41. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31575.
    PubMed     Text format     Abstract available


  42. GILL SE, McGree ME, Weaver AL, Cliby WA, et al
    Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gynecol Oncol. 2016 Dec 1. pii: S0090-8258(16)31577.
    PubMed     Text format     Abstract available


    November 2016
  43. SEAGLE BL, Butler SK, Strohl AE, Nieves-Neira W, et al
    Chemotherapy delay after primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31578.
    PubMed     Text format     Abstract available


  44. KARNEZIS AN, Cho KR
    Of mice and women - Non-ovarian origins of "ovarian" cancer.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31608.
    PubMed     Text format    


  45. SORIO R, Roemer-Becuwe C, Hilpert F, Gibbs E, et al
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31562.
    PubMed     Text format     Abstract available


  46. HEITZ F, Hengsbach A, Harter P, Traut A, et al
    Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2016 Nov 16. pii: S0090-8258(16)31567.
    PubMed     Text format     Abstract available


  47. CORDEIRO VIDAL G, Babin G, Querleu D, Guyon F, et al
    Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31507.
    PubMed     Text format     Abstract available


  48. LI Y, Zhang HL, Kang S, Zhou RM, et al
    The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31566.
    PubMed     Text format     Abstract available


  49. MARCHETTI C, Kristeleit R, McCormack M, Mould T, et al
    Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecol Oncol. 2016 Nov 5. pii: S0090-8258(16)31520.
    PubMed     Text format     Abstract available


    October 2016
  50. DESALE MG, Tanner EJ 3rd, Sinno AK, Angarita AA, et al
    Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31501.
    PubMed     Text format     Abstract available


  51. CHAN JK, Java JJ, Fuh K, Monk BJ, et al
    The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG oncology/gynecologic oncology group trials.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31421.
    PubMed     Text format     Abstract available


  52. LEE JY, Kim K, Lee YS, Kim HY, et al
    Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31498.
    PubMed     Text format     Abstract available


  53. CRAIG ER, Londono AI, Norian LA, Arend RC, et al
    Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31477.
    PubMed     Text format     Abstract available


  54. KIM HS, Bristow RE, Chang SJ
    Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31488.
    PubMed     Text format     Abstract available


  55. GARCIA-SOTO AE, Java JJ, Nieves Neira W, Pearson JM, et al
    Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31474.
    PubMed     Text format     Abstract available


  56. LIAO Y, Deng Y, Liu J, Ye Z, et al
    MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31410.
    PubMed     Text format     Abstract available


  57. SHAFRIR AL, Rice MS, Gupta M, Terry KL, et al
    The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status.
    Gynecol Oncol. 2016 Oct 5. pii: S0090-8258(16)31430.
    PubMed     Text format     Abstract available


  58. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Gynecol Oncol. 2016;143:3-15.
    PubMed     Text format     Abstract available


    September 2016
  59. MUELLER JJ, Kelly A, Zhou Q, Iasonos A, et al
    Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecol Oncol. 2016 Sep 28. pii: S0090-8258(16)31420.
    PubMed     Text format     Abstract available


  60. ROSE PG, Java JJ, Morgan MA, Alvarez-Secord A, et al
    Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Sep 27. pii: S0090-8258(16)31368.
    PubMed     Text format     Abstract available


  61. OH J, Barve M, Matthews CM, Koon EC, et al
    Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31424.
    PubMed     Text format     Abstract available


  62. FU Y, Biglia N, Wang Z, Shen Y, et al
    Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31427.
    PubMed     Text format     Abstract available


  63. CAMPBELL G, Hagan T, Gilbertson-White S, Houze M, et al
    Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2016 Sep 18. pii: S0090-8258(16)31414.
    PubMed     Text format     Abstract available


  64. KATO K, Nomura H, Nagashima M, Takeshima N, et al
    Secondary debulking surgery for isolated pelvic nodal recurrence requiring external iliac vein excision and reconstruction in a patient with ovarian cancer.
    Gynecol Oncol. 2016 Sep 11. pii: S0090-8258(16)31411.
    PubMed     Text format     Abstract available


  65. PINSKY PF, Yu K, Kramer BS, Black A, et al
    Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31361.
    PubMed     Text format     Abstract available


  66. SINGH S, Guetzko M, Resnick K
    Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31367.
    PubMed     Text format     Abstract available


  67. MELAMED A, Hinchcliff EM, Clemmer JT, Bregar AJ, et al
    Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31365.
    PubMed     Text format     Abstract available


  68. NAKAYAMA M, Kobayashi H, Takahara T, Nishimura Y, et al
    A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31357.
    PubMed     Text format     Abstract available


    August 2016
  69. NASSER S, Lazaridis A, Evangelou M, Jones B, et al
    Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Gynecol Oncol. 2016 Aug 29. pii: S0090-8258(16)31348.
    PubMed     Text format     Abstract available


  70. KALDAWY A, Segev Y, Lavie O, Auslender R, et al
    Low-grade serous ovarian cancer: A review.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31346.
    PubMed     Text format     Abstract available


  71. BRIGHTWELL RM, Grzankowski KS, Lele S, Eng K, et al
    The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31352.
    PubMed     Text format     Abstract available


  72. PAIK ES, Shim M, Choi HJ, Lee YY, et al
    Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
    Gynecol Oncol. 2016 Aug 23. pii: S0090-8258(16)31347.
    PubMed     Text format     Abstract available


  73. MONK BJ, Poveda A, Vergote I, Raspagliesi F, et al
    Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
    Gynecol Oncol. 2016 Aug 18. pii: S0090-8258(16)30983.
    PubMed     Text format     Abstract available


  74. HAY CM, Courtney-Brooks M, Lefkowits C, Hagan TL, et al
    Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?
    Gynecol Oncol. 2016 Aug 13. pii: S0090-8258(16)31258.
    PubMed     Text format     Abstract available


  75. TOZZI R, Traill Z, Garruto Campanile R, Ferrari F, et al
    Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31255.
    PubMed     Text format     Abstract available


  76. ALETTI GD, Cliby WA
    Time for centralizing patients with ovarian cancer: what are we waiting for?
    Gynecol Oncol. 2016;142:209-10.
    PubMed     Text format    


    July 2016
  77. SANTOIEMMA PP, Reyes C, Wang LP, McLane MW, et al
    Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30976.
    PubMed     Text format     Abstract available


  78. PETRICONE-WESTWOOD D, Lebel S
    Being a caregiver to patients with ovarian cancer: A scoping review of the literature.
    Gynecol Oncol. 2016 Jul 24. pii: S0090-8258(16)30876.
    PubMed     Text format     Abstract available


  79. KANSKA J, Zakhour M, Taylor-Harding B, Karlan BY, et al
    Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 23. pii: S0090-8258(16)30982.
    PubMed     Text format     Abstract available


  80. WILSON AJ, Sarfo-Kantanka K, Barrack T, Steck A, et al
    Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30957.
    PubMed     Text format     Abstract available


  81. TOZZI R, Gubbala K, Majd HS, Campanile RG, et al
    Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: Description of the technique and surgical outcomes.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30837.
    PubMed     Text format     Abstract available


  82. WANG D, Li C, Zhang Y, Wang M, et al
    Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30961.
    PubMed     Text format     Abstract available


  83. GUNDERSON CC, Ding K, Dvorak J, Moore KN, et al
    The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30972.
    PubMed     Text format     Abstract available


  84. MARTIN JY, Goff BA, Urban RR
    Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30829.
    PubMed     Text format     Abstract available


  85. GIANNAKEAS V, Sopik V, Narod SA
    A model for ovarian cancer progression based on inherent resistance.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30825.
    PubMed     Text format     Abstract available


  86. WALKER JL
    Intraperitoneal chemotherapy for ovarian cancer.
    Gynecol Oncol. 2016;142:1-2.
    PubMed     Text format    


    June 2016
  87. DE LEON M, Cardenas H, Vieth E, Emerson R, et al
    Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30828.
    PubMed     Text format     Abstract available


  88. ANDRIKOPOULOU M, Vetere P, Nezhat FR
    Ovarian cancer laparoscopic hysterectomy and staging in a patient with history of intraperitoneal renal transplant.
    Gynecol Oncol. 2016 Jun 7. pii: S0090-8258(16)30812.
    PubMed     Text format     Abstract available


  89. HIJAZ M, Chhina J, Mert I, Taylor M, et al
    Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Gynecol Oncol. 2016 Jun 6. pii: S0090-8258(16)30773.
    PubMed     Text format     Abstract available


  90. TSENG JH, Suidan RS, Zivanovic O, Gardner GJ, et al
    Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30764.
    PubMed     Text format     Abstract available


  91. SAWYER BT, LaFargue CJ, Bristow RE
    Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30769.
    PubMed     Text format     Abstract available


  92. BARBER EL, Rutstein SE, Miller WC, Gehrig PA, et al
    Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30767.
    PubMed     Text format    


    May 2016
  93. GOUY S, Ferron G, Glehen O, Bayar A, et al
    Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30760.
    PubMed     Text format     Abstract available


  94. HERNANDEZ L, Kim MK, Lyle LT, Bunch KP, et al
    Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30757.
    PubMed     Text format     Abstract available


  95. DAHM-KAHLER P, Palmqvist C, Staf C, Holmberg E, et al
    Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study.
    Gynecol Oncol. 2016 May 26. pii: S0090-8258(16)30754.
    PubMed     Text format     Abstract available


  96. KUMAR A, Moynagh MR, Multinu F, Cliby WA, et al
    Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Gynecol Oncol. 2016 May 25. pii: S0090-8258(16)30756.
    PubMed     Text format     Abstract available


  97. PETRILLO M, Amadio G, Salutari V, Paris I, et al
    Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Gynecol Oncol. 2016 May 20. pii: S0090-8258(16)30741.
    PubMed     Text format     Abstract available


  98. ATASEVEN B, Harter P, Grimm C, Heitz F, et al
    The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30745.
    PubMed     Text format     Abstract available


  99. SLAUGHTER K, Holman LL, Thomas EL, Gunderson CC, et al
    Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30744.
    PubMed     Text format     Abstract available


  100. POOLE EM, Konstantinopoulos PA, Terry KL
    Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30733.
    PubMed     Text format     Abstract available


  101. HUSAIN A, Wang Y, Hanker LC, Ojeda B, et al
    Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer.
    Gynecol Oncol. 2016 May 13. pii: S0090-8258(16)30730.
    PubMed     Text format     Abstract available


  102. TURNER TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, et al
    Ovarian cancer and the immune system - The role of targeted therapies.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30686.
    PubMed     Text format     Abstract available


  103. VATANSEVER D, Atici AE, Sozen H, Sakin O, et al
    Diaphragmatic resection preserving and repairing pericardium, splenectomy and distal pancreatectomy for interval debulking surgery of ovarian cancer.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30682.
    PubMed     Text format     Abstract available


  104. ZHANG D, Bai B, Xi Y, Wang T, et al
    Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30677.
    PubMed     Text format     Abstract available


    April 2016
  105. SUH DH, Kim HS, Chang SJ, Bristow RE, et al
    Surgical management of recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 26. pii: S0090-8258(16)30164.
    PubMed     Text format     Abstract available


  106. SZENDER JB, Eng KH, Matsuzaki J, Miliotto A, et al
    HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30150.
    PubMed     Text format     Abstract available


  107. SHALOWITZ DI, Epstein AJ, Ko EM, Giuntoli RL 2nd, et al
    Non-surgical management of ovarian cancer: Prevalence and implications.
    Gynecol Oncol. 2016 Apr 20. pii: S0090-8258(16)30158.
    PubMed     Text format     Abstract available


  108. RODRIGUEZ GC, Turbov J, Rosales R, Yoo J, et al
    Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30154.
    PubMed     Text format     Abstract available


  109. WALLBILLICH JJ, Forde B, Havrilesky LJ, Cohn DE, et al
    A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30156.
    PubMed     Text format     Abstract available


  110. VIZZIELLI G, Costantini B, Tortorella L, Pitruzzella I, et al
    A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment.
    Gynecol Oncol. 2016 Apr 18. pii: S0090-8258(16)30152.
    PubMed     Text format     Abstract available


  111. FENG Z, Wen H, Bi R, Yang W, et al
    Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Apr 17. pii: S0090-8258(16)30148.
    PubMed     Text format     Abstract available


  112. NAROD SA
    Talc and ovarian cancer.
    Gynecol Oncol. 2016 Apr 16. pii: S0090-8258(16)30139.
    PubMed     Text format    


  113. EGGINK FA, Mom CH, Kruitwagen RF, Reyners AK, et al
    Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
    Gynecol Oncol. 2016 Apr 15. pii: S0090-8258(16)30140.
    PubMed     Text format     Abstract available


  114. ZHOU Y, Irwin ML, Ferrucci LM, McCorkle R, et al
    Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors - I.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30106.
    PubMed     Text format     Abstract available


  115. ZHU X, Lang J
    The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review.
    Gynecol Oncol. 2016 Apr 7. pii: S0090-8258(16)30103.
    PubMed     Text format     Abstract available


  116. DORAYAPPAN KD, Wallbillich JJ, Cohn DE, Selvendiran K, et al
    The biological significance and clinical applications of exosomes in ovarian cancer.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30092.
    PubMed     Text format     Abstract available


  117. PETRILLO M, Nero C, Amadio G, Gallo D, et al
    Targeting the hallmarks of ovarian cancer: The big picture.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30093.
    PubMed     Text format     Abstract available


  118. NOER MC, Sperling CD, Antonsen SL, Ottesen B, et al
    A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30090.
    PubMed     Text format     Abstract available


  119. ALVAREZ RD, Matulonis UA, Herzog TJ, Coleman RL, et al
    Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 3. pii: S0090-8258(16)30063.
    PubMed     Text format    


  120. WINTERHOFF B, Hamidi H, Wang C, Kalli KR, et al
    Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
    Gynecol Oncol. 2016;141:95-100.
    PubMed     Text format     Abstract available


  121. ZHANG M, Liu G, Xue F, Edwards R, et al
    Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    Gynecol Oncol. 2016;141:57-64.
    PubMed     Text format     Abstract available


  122. MURAKAMI R, Matsumura N, Brown JB, Wang Z, et al
    Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
    Gynecol Oncol. 2016;141:49-56.
    PubMed     Text format     Abstract available


  123. TINQUAUT F, Freyer G, Chauvin F, Gane N, et al
    Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials.
    Gynecol Oncol. 2016 Apr 1. pii: S0090-8258(16)30074.
    PubMed     Text format     Abstract available


  124. MUNKARAH A, Mert I, Chhina J, Hamid S, et al
    Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
    Gynecol Oncol. 2016;141:72-9.
    PubMed     Text format     Abstract available


  125. JANCO JM, Kumar A, Weaver AL, McGree ME, et al
    Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
    Gynecol Oncol. 2016;141:140-7.
    PubMed     Text format     Abstract available


    March 2016
  126. SHARROW AC, Perkins B, Collector MI, Yu W, et al
    Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy.
    Gynecol Oncol. 2016 Mar 24. pii: S0090-8258(16)30077.
    PubMed     Text format     Abstract available


  127. YANARANOP M, Tiyayon J, Siricharoenthai S, Nakrangsee S, et al
    Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass.
    Gynecol Oncol. 2016 Mar 17. pii: S0090-8258(16)30075.
    PubMed     Text format     Abstract available


  128. HEITZ F, Harter P, Alesina PF, Walz MK, et al
    Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30070.
    PubMed     Text format     Abstract available


  129. PRADER S, Harter P, Grimm C, Traut A, et al
    Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer.
    Gynecol Oncol. 2016 Mar 10. pii: S0090-8258(16)30069.
    PubMed     Text format     Abstract available


  130. WEBB JR, Milne K, Kroeger DR, Nelson BH, et al
    PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2016 Mar 10. pii: S0090-8258(16)30065.
    PubMed     Text format     Abstract available


  131. MILLER KR, Patel JN, Ganapathi MK, Tait DL, et al
    Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.
    Gynecol Oncol. 2016 Mar 5. pii: S0090-8258(16)30061.
    PubMed     Text format     Abstract available


  132. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Equivalency challenge: Evaluation of lipodox(R) as the generic equivalent for doxil(R) in a human ovarian cancer orthotropic mouse model.
    Gynecol Oncol. 2016 Mar 2. pii: S0090-8258(16)30057.
    PubMed     Text format     Abstract available


    February 2016
  133. NAROD SA, Sopik V, Giannakeas V
    Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30044.
    PubMed     Text format    


  134. CHUNDURY A, Apicelli A, DeWees T, Powell M, et al
    Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.
    Gynecol Oncol. 2016 Feb 10. pii: S0090-8258(16)30031.
    PubMed     Text format     Abstract available


  135. NASIOUDIS D, Sisti G, Kanninen TT, Holcomb K, et al
    Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study.
    Gynecol Oncol. 2016 Feb 8. pii: S0090-8258(16)30030.
    PubMed     Text format     Abstract available


  136. BRADFORD A, Shinn E
    Incorporating Patient Perspectives and Priorities into Clinical Trial Design.
    Gynecol Oncol. 2016;140:191-2.
    PubMed     Text format    


    January 2016
  137. KONECNY GE, Winterhoff B, Wang C
    Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.
    Gynecol Oncol. 2016 Jan 28. pii: S0090-8258(16)30024.
    PubMed     Text format     Abstract available


  138. GREGGI S, Falcone F, Carputo R, Raspagliesi F, et al
    Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
    Gynecol Oncol. 2016 Jan 26. pii: S0090-8258(16)30023.
    PubMed     Text format     Abstract available


  139. YOSHIDA A, Derchain SF, Pitta DR, De Angelo Andrade LA, et al
    Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
    Gynecol Oncol. 2016 Jan 26. pii: S0090-8258(16)30021.
    PubMed     Text format     Abstract available


  140. GRABOWSKI JP, Harter P, Heitz F, Pujade-Lauraine E, et al
    Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Gynecol Oncol. 2016 Jan 22. pii: S0090-8258(16)30020.
    PubMed     Text format     Abstract available


  141. WESTIN SN, Randall L
    The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics.
    Gynecol Oncol. 2016 Jan 22. pii: S0090-8258(16)00040.
    PubMed     Text format    


  142. GUELI ALLETTI S, Rossitto C, Cianci S, Scambia G, et al
    Telelap ALF-X total hysterectomy for early stage endometrial cancer: New frontier of robotic gynecological surgery.
    Gynecol Oncol. 2016 Jan 21. pii: S0090-8258(16)30018.
    PubMed     Text format    


  143. ROMAGNOLO C, Leon AE, Fabricio AS, Taborelli M, et al
    HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Gynecol Oncol. 2016 Jan 19. pii: S0090-8258(16)30015.
    PubMed     Text format     Abstract available


  144. KATO K, Katsuda T, Takeshima N
    Cytoreduction of diaphragmatic metastasis from ovarian cancer with involvement of the liver using a ventral liver mobilization technique.
    Gynecol Oncol. 2016 Jan 19. pii: S0090-8258(16)30017.
    PubMed     Text format     Abstract available


  145. WEBERPALS JI, Amin MS, Chen BE, Tu D, et al
    First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.
    Gynecol Oncol. 2016 Jan 13. pii: S0090-8258(16)30013.
    PubMed     Text format     Abstract available


  146. WOOPEN H, Richter R, Ismaeel F, Chekerov R, et al
    The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
    Gynecol Oncol. 2016 Jan 11. pii: S0090-8258(16)30012.
    PubMed     Text format     Abstract available


  147. MUELLER JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, et al
    Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Gynecol Oncol. 2016 Jan 9. pii: S0090-8258(16)30008.
    PubMed     Text format     Abstract available


  148. HINCHCLIFF E, Rauh-Hain JA, Clemmer JT, Diver E, et al
    Racial disparities in survival in malignant germ cell tumors of the ovary.
    Gynecol Oncol. 2016 Jan 7. pii: S0090-8258(16)30006.
    PubMed     Text format     Abstract available


  149. LU L, Katsaros D, Canuto EM, Biglia N, et al
    LIN-28B/let-7a/IGF-II Axis Molecular Subtypes are Associated with Epithelial Ovarian Cancer Prognosis.
    Gynecol Oncol. 2016 Jan 2. pii: S0090-8258(15)30238.
    PubMed     Text format     Abstract available


  150. JOHANSEN N, Liavaag AH, Tanbo TG, Dahl AA, et al
    Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Gynecol Oncol. 2016;140:101-6.
    PubMed     Text format     Abstract available


  151. PRESCOTT LS, Dickens AS, Guerra SL, Tanha JM, et al
    Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education.
    Gynecol Oncol. 2016;140:114-9.
    PubMed     Text format     Abstract available


    December 2015
  152. WONG A, Kuick CH, Wong WL, Tham JM, et al
    Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with Grade 3 endometrioid endometrial carcinomas.
    Gynecol Oncol. 2015 Dec 31. pii: S0090-8258(15)30234.
    PubMed     Text format     Abstract available


  153. ERIKSSON AG, Ducie J, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.
    Gynecol Oncol. 2015 Dec 30. pii: S0090-8258(15)30231.
    PubMed     Text format     Abstract available


  154. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    Ovarian cancer outcomes: Predictors of early death.
    Gynecol Oncol. 2015 Dec 29. pii: S0090-8258(15)30224.
    PubMed     Text format     Abstract available


  155. HARTER P, Johnson T, Berton-Rigaud D, Park SY, et al
    BRCA1/2 Mutations Associated with Progression-Free Survival in Ovarian Cancer Patients in the AGO-OVAR 16 Study.
    Gynecol Oncol. 2015 Dec 28. pii: S0090-8258(15)30230.
    PubMed     Text format     Abstract available


  156. VAN DER STEEN SC, van Tilborg AA, Vallen MJ, Bulten J, et al
    Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11.
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30227.
    PubMed     Text format     Abstract available


  157. EMONS G, Kurzeder C, Schmalfeldt B, Neuser P, et al
    Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8).
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30229.
    PubMed     Text format     Abstract available


  158. BOAC BM, Xiong Y, Marchion DC, Abbasi F, et al
    Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30228.
    PubMed     Text format     Abstract available


  159. DOMCHEK SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, et al
    Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Gynecol Oncol. 2015 Dec 23. pii: S0090-8258(15)30223.
    PubMed     Text format     Abstract available


  160. TAUBE ET, Denkert C, Sehouli J, Kunze CA, et al
    Wilms tumor protein 1 (WT1) - Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2015 Dec 22. pii: S0090-8258(15)30221.
    PubMed     Text format     Abstract available


  161. BERNARDS SS, Norquist BM, Harrell MI, Agnew KJ, et al
    Genetic characterization of early onset ovarian carcinoma.
    Gynecol Oncol. 2015 Dec 21. pii: S0090-8258(15)30220.
    PubMed     Text format     Abstract available


  162. CHEN X, Gong L, Ou R, Zheng Z, et al
    Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752.
    Gynecol Oncol. 2015 Dec 15. pii: S0090-8258(15)30215.
    PubMed     Text format     Abstract available


  163. ATASEVEN B, Grimm C, Harter P, Heitz F, et al
    Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30211.
    PubMed     Text format     Abstract available


  164. VOGEL TJ, Jeon C, Karlan B, Walsh C, et al
    Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30207.
    PubMed     Text format     Abstract available


  165. SOLEYMANI MAJD H, Ferrari F, Manek S, Gubbala K, et al
    Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30208.
    PubMed     Text format     Abstract available


  166. NGUYEN TM, Shin IW, Lee TJ, Park J, et al
    Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30210.
    PubMed     Text format     Abstract available


  167. COOK LS, Leung AC, Swenerton K, Gallagher RP, et al
    Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30209.
    PubMed     Text format     Abstract available


    November 2015
  168. KIM KH, Jelovac D, Armstrong DK, Schwartz B, et al
    Phase 1b Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 Nov 28. pii: S0090-8258(15)30203.
    PubMed     Text format     Abstract available


  169. MINION LE, Coleman RL, Alvarez RD, Herzog TJ, et al
    Endpoints in clinical trials: What do patients consider important? A survey of the ovarian cancer national alliance.
    Gynecol Oncol. 2015 Nov 26. pii: S0090-8258(15)30202.
    PubMed     Text format     Abstract available


  170. VOS JR, Mourits MJ, Teixeira N, Jansen L, et al
    Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
    Gynecol Oncol. 2015 Nov 26. pii: S0090-8258(15)30201.
    PubMed     Text format     Abstract available


  171. SEROR J, Bats AS, Habchi H, Lecuru F, et al
    Optimal surgical cytoreduction of the upper abdomen and the diaphragm for advanced ovarian cancer using plasmajet energy.
    Gynecol Oncol. 2015 Nov 24. pii: S0090-8258(15)30200.
    PubMed     Text format     Abstract available


  172. CHEN CH, Shyu MK, Wang SW, Chou CH, et al
    MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin beta1 pathway.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30197.
    PubMed     Text format     Abstract available


  173. BURTON ER, Brady M, Homesley HD, Rose PG, et al
    A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30199.
    PubMed     Text format     Abstract available


  174. LANDRUM LM, Brady WE, Armstrong DK, Moore KN, et al
    A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30196.
    PubMed     Text format     Abstract available


  175. RUTTEN IJ, van de Laar R, Kruitwagen RF, Bakers FC, et al
    Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography.
    Gynecol Oncol. 2015 Nov 19. pii: S0090-8258(15)30194.
    PubMed     Text format     Abstract available


  176. KOTSOPOULOS J, Rosen B, Fan I, Moody J, et al
    Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
    Gynecol Oncol. 2015 Nov 7. pii: S0090-8258(15)30181.
    PubMed     Text format     Abstract available


  177. KELEMEN LE, Warren GW, Koziak JM, Kobel M, et al
    Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer.
    Gynecol Oncol. 2015 Nov 5. pii: S0090-8258(15)30180.
    PubMed     Text format     Abstract available


  178. BOUCHARD-FORTIER G, Rosen B, Vyarvelska I, Pasetka M, et al
    A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Gynecol Oncol. 2015 Nov 4. pii: S0090-8258(15)30177.
    PubMed     Text format     Abstract available


  179. CALLEGARO-FILHO D, Gershenson DM, Nick AM, Munsell MF, et al
    Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
    Gynecol Oncol. 2015 Nov 4. pii: S0090-8258(15)30176.
    PubMed     Text format     Abstract available


  180. KUMAR A, Janco JM, Mariani A, Bakkum-Gamez JN, et al
    Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2015 Nov 2. pii: S0090-8258(15)30172.
    PubMed     Text format     Abstract available


  181. HASMAD HN, Lai KN, Wen WX, Park DJ, et al
    Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Gynecol Oncol. 2015 Nov 2. pii: S0090-8258(15)30173.
    PubMed     Text format     Abstract available


  182. NORQUIST BM, Swisher EM
    More genes, more problems? Benefits and risks of multiplex genetic testing.
    Gynecol Oncol. 2015;139:209-10.
    PubMed     Text format    


  183. CHOI HJ, Heo EJ, Paik E, Kim TJ, et al
    Laparo-endoscopic single site paraaortic lymphadenectomy facilitated by a new articulating vessel sealing device.
    Gynecol Oncol. 2015;139:385-6.
    PubMed     Text format    


  184. FREY MK, Kim SH, Bassett RY, Martineau J, et al
    Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
    Gynecol Oncol. 2015;139:211-5.
    PubMed     Text format     Abstract available


    October 2015
  185. REYES HD, Carlson MJ, Devor EJ, Zhang Y, et al
    Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Gynecol Oncol. 2015 Oct 30. pii: S0090-8258(15)30170.
    PubMed     Text format     Abstract available


  186. BUAS MF, Gu H, Djukovic D, Zhu J, et al
    Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
    Gynecol Oncol. 2015 Oct 29. pii: S0090-8258(15)30168.
    PubMed     Text format     Abstract available


  187. TUULIA V, Anniina P, Annika A, Olli C, et al
    F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2015 Oct 26. pii: S0090-8258(15)30166.
    PubMed     Text format     Abstract available


  188. YANG YF, Liao YY, Liu XL, Su SG, et al
    Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
    Gynecol Oncol. 2015 Oct 19. pii: S0090-8258(15)30163.
    PubMed     Text format     Abstract available


  189. MIKAMI M, Tanabe K, Matsuo K, Miyazaki Y, et al
    Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
    Gynecol Oncol. 2015 Oct 18. pii: S0090-8258(15)30161.
    PubMed     Text format     Abstract available


  190. CHEN X, Dong C, Law PT, Chan MT, et al
    MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Gynecol Oncol. 2015 Oct 16. pii: S0090-8258(15)30157.
    PubMed     Text format     Abstract available


  191. LHEUREUX S, Karakasis K, Harter P, Scott C, et al
    Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Gynecol Oncol. 2015 Oct 14. pii: S0090-8258(15)30159.
    PubMed     Text format     Abstract available


  192. CELIK M, Tasci T, Basaran D, Tulunay G, et al
    Step by step right upper quadrant cytoreduction guided by computed tomography in advanced ovarian cancer.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30155.
    PubMed     Text format    


  193. HUANG T, Poole EM, Okereke OI, Kubzansky LD, et al
    Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30153.
    PubMed     Text format     Abstract available


  194. HESS LM, Huang HQ, Hanlon AL, Robinson WR, et al
    Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30152.
    PubMed     Text format     Abstract available


  195. MANCHANDA R, Legood R, Pearce L, Menon U, et al
    Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
    Gynecol Oncol. 2015 Oct 2. pii: S0090-8258(15)30150.
    PubMed     Text format     Abstract available


  196. RAMIREZ PT
    Upping the ante in assessing the feasibility of surgical cytoreduction for advanced ovarian cancer: A modified laparoscopic Predictive Index score.
    Gynecol Oncol. 2015;139:1-2.
    PubMed     Text format    


  197. SCHWAB CL, English DP, Black J, Bellone S, et al
    Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
    Gynecol Oncol. 2015;139:112-7.
    PubMed     Text format     Abstract available


  198. NOVAK M, Lester J, Karst AM, Parkash V, et al
    Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2015;139:104-11.
    PubMed     Text format     Abstract available


    September 2015
  199. BARBER EL, Rutstein S, Miller WC, Gehrig PA, et al
    A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery.
    Gynecol Oncol. 2015 Sep 29. pii: S0090-8258(15)30141.
    PubMed     Text format     Abstract available


  200. ANDERSEN CL, Eskelund CW, Siersma VD, Felding P, et al
    is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?
    Gynecol Oncol. 2015 Sep 22. pii: S0090-8258(15)30133.
    PubMed     Text format    


  201. O'HANLAN KA, Sten MS, O'Holleran MS, Ford NN, et al
    Infrarenal lymphadenectomy for gynecological malignancies: Two laparoscopic approaches.
    Gynecol Oncol. 2015 Sep 22. pii: S0090-8258(15)30135.
    PubMed     Text format     Abstract available


  202. SHU CA, Zhou Q, Jotwani AR, Iasonos A, et al
    Ovarian clear cell carcinoma, outcomes by stage: The MSK experience.
    Gynecol Oncol. 2015 Sep 21. pii: S0090-8258(15)30132.
    PubMed     Text format     Abstract available


  203. GALVAN-TURNER VB, Chang J, Ziogas A, Bristow RE, et al
    Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
    Gynecol Oncol. 2015 Sep 17. pii: S0090-8258(15)30131.
    PubMed     Text format     Abstract available


  204. TRETARRE B, Molinie F, Woronoff AS, Bossard N, et al
    Ovarian cancer in France: Trends in incidence, mortality and survival, 1980-2012.
    Gynecol Oncol. 2015 Sep 14. pii: S0090-8258(15)30130.
    PubMed     Text format     Abstract available


  205. ENG KH, Hanlon BM, Bradley WH, Brian Szender J, et al
    Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Gynecol Oncol. 2015 Sep 14. pii: S0090-8258(15)30128.
    PubMed     Text format     Abstract available


  206. LOKICH E, Palisoul M, Romano N, Craig Miller M, et al
    Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.
    Gynecol Oncol. 2015 Sep 11. pii: S0090-8258(15)30127.
    PubMed     Text format     Abstract available


  207. ALTMAN AD, Ferguson SE, Atenafu EG, Kobel M, et al
    Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behaviour of high risk endometrial cancers.
    Gynecol Oncol. 2015 Sep 6. pii: S0090-8258(15)30119.
    PubMed     Text format     Abstract available


  208. BECKER JH, Ezendam NP, Boll D, van der Aa M, et al
    Effects of surgical volumes on the survival of endometrial carcinoma.
    Gynecol Oncol. 2015 Sep 5. pii: S0090-8258(15)30118.
    PubMed     Text format    


  209. LIU Z, Beach JA, Agadjanian H, Jia D, et al
    Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.
    Gynecol Oncol. 2015 Sep 5. pii: S0090-8258(15)30117.
    PubMed     Text format     Abstract available


  210. URBAN N, Hawley S, Janes H, Karlan BY, et al
    Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
    Gynecol Oncol. 2015 Sep 3. pii: S0090-8258(15)30115.
    PubMed     Text format     Abstract available


  211. KASHIMA H, Wu RC, Wang Y, Sinno A, et al
    Laminin C1 Expression by Uterine Carcinoma Cells Is Associated with Tumor Progression.
    Gynecol Oncol. 2015 Sep 3. pii: S0090-8258(15)30116.
    PubMed     Text format     Abstract available


  212. GIANNAKEAS V, Sopik V, Shestopaloff K, Iqbal J, et al
    A Model for Estimating Ovarian Cancer Risk: Application for Preventive Oophorectomy.
    Gynecol Oncol. 2015 Sep 2. pii: S0090-8258(15)30112.
    PubMed     Text format     Abstract available


  213. CHEN J, Xi B, Zhao Y, Yu Y, et al
    Retraction notice to "High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer" [Gynecol. Oncol. 126 (2012) 109-117].
    Gynecol Oncol. 2015;138:764.
    PubMed     Text format    


  214. MEISEL JL, Woo KM, Sudarsan N, Eng J, et al
    Development of a risk stratification system to guide treatment for female germ cell tumors.
    Gynecol Oncol. 2015;138:566-72.
    PubMed     Text format     Abstract available


  215. FELIX AS, Scott McMeekin D, Mutch D, Walker JL, et al
    Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 Trial.
    Gynecol Oncol. 2015 Sep 1. pii: S0090-8258(15)30113.
    PubMed     Text format     Abstract available


  216. GARCIA C, Lyon L, Conell C, Littell RD, et al
    Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2015;138:723-6.
    PubMed     Text format     Abstract available


    August 2015
  217. NAKAMURA M, Ono YJ, Kanemura M, Tanaka T, et al
    Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
    Gynecol Oncol. 2015 Aug 31. pii: S0090-8258(15)30102.
    PubMed     Text format     Abstract available


  218. DUSKA LR, Java JJ, Cohn DE, Burger RA, et al
    Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Gynecol Oncol. 2015 Aug 31. pii: S0090-8258(15)30103.
    PubMed     Text format     Abstract available


  219. ELIAS KM, Emori MM, Papp E, MacDuffie E, et al
    Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research.
    Gynecol Oncol. 2015 Aug 29. pii: S0090-8258(15)30109.
    PubMed     Text format     Abstract available


  220. SEIFERT H, Georgiou A, Alexander H, McLachlan J, et al
    Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2015 Aug 26. pii: S0090-8258(15)30107.
    PubMed     Text format     Abstract available


  221. SMITH HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, et al
    PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2015 Aug 21. pii: S0090-8258(15)30105.
    PubMed     Text format     Abstract available


  222. SMITS A, Smits E, Lopes A, Das N, et al
    Body Mass Index, Physical Activity and Quality of Life of Ovarian Cancer Survivors: Time to Get Moving? Two-centre study.
    Gynecol Oncol. 2015 Aug 17. pii: S0090-8258(15)30099.
    PubMed     Text format     Abstract available


  223. AGHAJANIAN C, Goff B, Nycum LR, Wang YV, et al
    Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2015 Aug 10. pii: S0090-8258(15)30098.
    PubMed     Text format     Abstract available


  224. SIAMAKPOUR-REIHANI S, Owzar K, Jiang C, Turner T, et al
    Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2015 Aug 7. pii: S0090-8258(15)30095.
    PubMed     Text format     Abstract available


  225. LHEUREUX S, Shaw PA, Karakasis K, Oza AM, et al
    Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    Gynecol Oncol. 2015;138:235-7.
    PubMed     Text format    


  226. FOSSATI M, Buzzonetti A, Monego G, Catzola V, et al
    Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAMxanti-CD3).
    Gynecol Oncol. 2015;138:343-51.
    PubMed     Text format     Abstract available


  227. OZGUL N, Basaran D, Boyraz G, Salman MC, et al
    Hemostatic control of inferior vena cava with tape traction maneuver in the presence of bulky metastatic paraaortic lymph nodes.
    Gynecol Oncol. 2015;138:492-3.
    PubMed     Text format    


  228. WILSON MK, Fong P, Mesnage S, Chrystal K, et al
    Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.
    Gynecol Oncol. 2015;138:285-91.
    PubMed     Text format     Abstract available


    July 2015
  229. MATSUO K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, et al
    Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia.
    Gynecol Oncol. 2015 Jul 31. pii: S0090-8258(15)30092.
    PubMed     Text format     Abstract available


  230. LI D, Ding CY, Qiu LH
    Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30093.
    PubMed     Text format     Abstract available


  231. NEFF R, Havrilesky LJ, Chino J, O'Malley DM, et al
    Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30064.
    PubMed     Text format     Abstract available


  232. CHAN JL, Letourneau J, Salem W, Cil AP, et al
    Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30090.
    PubMed     Text format     Abstract available


  233. NYMOEN DA, Hetland Falkenthal TE, Holth A, Siong OG, et al
    Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Gynecol Oncol. 2015 Jul 28. pii: S0090-8258(15)30091.
    PubMed     Text format     Abstract available


  234. FERRISS JS, Java JJ, Bookman MA, Fleming GF, et al
    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study.
    Gynecol Oncol. 2015 Jul 26. pii: S0090-8258(15)30088.
    PubMed     Text format     Abstract available


  235. LIANG MI, ElNaggar AC, Nekkanti S, O'Malley DM, et al
    Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2015 Jul 24. pii: S0090-8258(15)30081.
    PubMed     Text format     Abstract available


  236. PETRILLO M, Vizzielli G, Fanfani F, Gallotta V, et al
    Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept.
    Gynecol Oncol. 2015 Jul 18. pii: S0090-8258(15)30080.
    PubMed     Text format     Abstract available


  237. ZHANG Y, Goodfellow R, Li Y, Yang S, et al
    NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.
    Gynecol Oncol. 2015 Jul 17. pii: S0090-8258(15)30084.
    PubMed     Text format     Abstract available


  238. BARGHOUT SH, Zepeda N, Vincent K, Azad AK, et al
    RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Gynecol Oncol. 2015 Jul 15. pii: S0090-8258(15)30070.
    PubMed     Text format     Abstract available


  239. LIN KY, Miller DS, Bailey AA, Andrews SJ, et al
    Ovarian involvement in endometrioid adenocarcinoma of uterus.
    Gynecol Oncol. 2015 Jul 14. pii: S0090-8258(15)30073.
    PubMed     Text format     Abstract available


  240. WOOPEN H, Richter R, Chekerov R, Siepmann T, et al
    The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological On
    Gynecol Oncol. 2015 Jul 13. pii: S0090-8258(15)30068.
    PubMed     Text format     Abstract available


  241. TZORTZATOS G, Andersson E, Soller M, Askmalm MS, et al
    The gynecological surveillance of women with Lynch syndrome in Sweden.
    Gynecol Oncol. 2015 Jul 12. pii: S0090-8258(15)30078.
    PubMed     Text format     Abstract available


  242. COHN DE, Havrilesky LJ, Osann K, Lipscomb J, et al
    Consensus in Controversy: The Modified Delphi Method Applied to Gynecologic Oncology Practice.
    Gynecol Oncol. 2015 Jul 12. pii: S0090-8258(15)30075.
    PubMed     Text format     Abstract available


  243. GRAYBILL W, Sood AK, Monk BJ, Coleman RL, et al
    State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer.
    Gynecol Oncol. 2015 Jul 9. pii: S0090-8258(15)00984.
    PubMed     Text format    


  244. ATASEVEN B, du Bois A, Reinthaller A, Traut A, et al
    Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Gynecol Oncol. 2015 Jul 8. pii: S0090-8258(15)30067.
    PubMed     Text format     Abstract available


  245. FUH KC, Secord AA, Bevis KS, Huh W, et al
    Comparison of Bevacizumab Alone or with Chemotherapy in Recurrent Ovarian Cancer Patients.
    Gynecol Oncol. 2015 Jul 2. pii: S0090-8258(15)30062.
    PubMed     Text format     Abstract available


  246. ZIGHELBOIM I, Ali S, Lankes HA, Backes F, et al
    Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2015 Jul 2. pii: S0090-8258(15)30059.
    PubMed     Text format     Abstract available


  247. FEBBRARO T, Robison K, Wilbur JS, Laprise J, et al
    Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
    Gynecol Oncol. 2015;138:109-14.
    PubMed     Text format     Abstract available


  248. BONNETERRE J, Hutt E, Bosq J, Graham JD, et al
    Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Gynecol Oncol. 2015 Jul 1. pii: S0090-8258(15)30058.
    PubMed     Text format     Abstract available


    June 2015
  249. VAN KRUCHTEN M, van der Marel P, de Munck L, Hollema H, et al
    Hormone Receptors as a Marker of Poor Survival in Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30050.
    PubMed     Text format     Abstract available


  250. TAYLOR SE, Li R, Petschauer JS, Donovan H, et al
    Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30047.
    PubMed     Text format     Abstract available


  251. STRINGER-REASOR EM, Baker GM, Skor MN, Kocherginsky M, et al
    Glucocorticoid Receptor Activation Inhibits Chemotherapy-induced Cell Death in High-grade Serous Ovarian Carcinoma.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30051.
    PubMed     Text format     Abstract available


  252. ERRIQUEZ J, Becco P, Olivero M, Ponzone R, et al
    TOP2A gene copy gain predicts response of epithelial ovarian cancers to liposomal pegylated doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Gynecol Oncol. 2015 Jun 19. pii: S0090-8258(15)30046.
    PubMed     Text format     Abstract available


  253. BURGER IA, Goldman DA, Vargas HA, Kattan MW, et al
    Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2015 Jun 17. pii: S0090-8258(15)30032.
    PubMed     Text format     Abstract available


  254. CASCALES P, Gil J, Feliciangeli E, Gil E, et al
    Hipec in ovarian cancer: Treatment of a new era or is it the end of the pipeline?
    Gynecol Oncol. 2015 Jun 16. pii: S0090-8258(15)30035.
    PubMed     Text format     Abstract available


  255. KARLSEN MA, Hogdall EV, Christensen IJ, Borgfeldt C, et al
    A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Gynecol Oncol. 2015 Jun 15. pii: S0090-8258(15)30041.
    PubMed     Text format     Abstract available


  256. SOPIK V, Rosen B, Giannakeas V, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part III. Prospects for the Future.
    Gynecol Oncol. 2015 Jun 15. pii: S0090-8258(15)30040.
    PubMed     Text format     Abstract available


  257. DECOLLOGNE S, Joshi S, Chung SA, Luk PP, et al
    Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30037.
    PubMed     Text format     Abstract available


  258. SOPIK V, Iqbal J, Rosen B, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part II. Case-fatality.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30038.
    PubMed     Text format     Abstract available


  259. SOPIK V, Iqbal J, Rosen B, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part I. Incidence.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30039.
    PubMed     Text format     Abstract available


  260. DOTTINO JA, Cliby WA, Myers ER, Bristow RE, et al
    Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention.
    Gynecol Oncol. 2015 Jun 10. pii: S0090-8258(15)30034.
    PubMed     Text format     Abstract available


  261. DINKELSPIEL HE, Champer M, Hou J, Tergas A, et al
    Long-term mortality among women with epithelial ovarian cancer.
    Gynecol Oncol. 2015 Jun 5. pii: S0090-8258(15)30028.
    PubMed     Text format     Abstract available


  262. MITRA A, Davis DA, Tomar S, Roy L, et al
    In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Gynecol Oncol. 2015 Jun 4. pii: S0090-8258(15)30020.
    PubMed     Text format     Abstract available


  263. SCHRAUWEN S, Coenegrachts L, Cattaneo A, Hermans E, et al
    The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
    Gynecol Oncol. 2015 Jun 4. pii: S0090-8258(15)30027.
    PubMed     Text format     Abstract available


  264. LAFARGUE CJ, Bristow RE
    Transdiaphragmatic Cardiophrenic Lymph Node Resection for Stage IV Ovarian Cancer.
    Gynecol Oncol. 2015 Jun 3. pii: S0090-8258(15)30025.
    PubMed     Text format     Abstract available


    May 2015
  265. TRAN AQ, Cohen JG, Li AJ
    Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30015.
    PubMed     Text format     Abstract available


  266. SUIDAN RS, Leitao MM Jr, Zivanovic O, Gardner GJ, et al
    Predictive value of the age-adjusted charlson comorbidity index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30014.
    PubMed     Text format     Abstract available


  267. PREVIS R, Leath CA 3rd, Coleman RL, Herzog TJ, et al
    Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30017.
    PubMed     Text format     Abstract available


  268. PEEL AB, Barlow CE, Leonard D, DeFina LF, et al
    Cardiorespiratory Fitness in Survivors of Cervical, Endometrial, and Ovarian Cancer: The Cooper Center Longitudinal Study.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30009.
    PubMed     Text format     Abstract available


  269. SMALETZ O, Diz MD, do Carmo CC, Sabbaga J, et al
    A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30005.
    PubMed     Text format     Abstract available


  270. BOONE JD, Dobbin ZC, Michael Straughn J, Buchsbaum DJ, et al
    Ovarian and cervical cancer patient derived xenografts: the past, present, and future.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30004.
    PubMed     Text format     Abstract available


  271. SCALICI J, Finan MA, Black J, Harmon MD, et al
    Minority participation in Gynecologic Oncology Group (GOG) Studies.
    Gynecol Oncol. 2015 May 22. pii: S0090-8258(15)00932.
    PubMed     Text format     Abstract available


  272. TOZZI R, Giannice R, Cianci S, Tardino S, et al
    Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2015 May 21. pii: S0090-8258(15)00915.
    PubMed     Text format     Abstract available


  273. GUTH U, Arndt V, Stadlmann S, Huang DJ, et al
    Epidemiology in ovarian carcinoma: lessons from autopsy.
    Gynecol Oncol. 2015 May 21. pii: S0090-8258(15)00921.
    PubMed     Text format     Abstract available


  274. KOLOMEYEVSKAYA N, Eng KH, Khan AN, Grzankowski KS, et al
    Cytokine Profiling of Ascites at Primary Surgery Identifies an Interaction of Tumor Necrosis Factor-alpha and Interleukin-6 in Predicting Reduced Progression-Free Survival in Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 May 19. pii: S0090-8258(15)00914.
    PubMed     Text format     Abstract available


  275. RABAN O, Peled Y, Krissi H, Goldberg N, et al
    The Significance of Paracardiac Lymph-Node Enlargement In Patients With Newly Diagnosed Stage IIIC Ovarian Cancer.
    Gynecol Oncol. 2015 May 19. pii: S0090-8258(15)00912.
    PubMed     Text format     Abstract available


  276. BROWN AJ, Sun CC, Urbauer DL, Bodurka DC, et al
    Feeling Powerless: Locus of Control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients.
    Gynecol Oncol. 2015 May 16. pii: S0090-8258(15)00874.
    PubMed     Text format     Abstract available


  277. PATANKAR S, Burke WM, Hou JY, Tergas AI, et al
    Risk stratification and outcomes of women undergoing surgery for ovarian cancer.
    Gynecol Oncol. 2015 May 11. pii: S0090-8258(15)00866.
    PubMed     Text format     Abstract available


  278. ESCAYOLA, Ferron G, Romeo M, Torrent JJ, et al
    The impact of pleural disease on the management of advanced ovarian cancer.
    Gynecol Oncol. 2015 May 9. pii: S0090-8258(15)00872.
    PubMed     Text format     Abstract available


  279. DITTO A, Martinelli F, Bogani G, Lorusso D, et al
    Long-term Safety of Fertility Sparing Surgery in Early Stage Ovarian Cancer: Comparison to Standard Radical Surgical Procedures.
    Gynecol Oncol. 2015 May 9. pii: S0090-8258(15)00873.
    PubMed     Text format     Abstract available


  280. SEAGLE BL, Yang CP, Eng KH, Dandapani M, et al
    TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
    Gynecol Oncol. 2015 May 6. pii: S0090-8258(15)00868.
    PubMed     Text format     Abstract available


  281. TEMKIN SM
    "Less is more:" The harms of overtreatment in early ovarian cancer.
    Gynecol Oncol. 2015;137:191-2.
    PubMed     Text format    


    April 2015
  282. SCHRAUWEN S, Depreeuw J, Coenegrachts L, Hermans E, et al
    Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Gynecol Oncol. 2015 Apr 28. pii: S0090-8258(15)00857.
    PubMed     Text format     Abstract available


  283. RAGHAVAN S, Ward MR, Katelyn R Rowleyb RM, Mehta G, et al
    Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.
    Gynecol Oncol. 2015 Apr 22. pii: S0090-8258(15)00833.
    PubMed     Text format     Abstract available


  284. MELISSA H, Jenny C, Fong L, Argyrios Z, et al
    Socioeconomic Status as a Predictor of Adherence to Treatment Guidelines for Early-Stage Ovarian Cancer.
    Gynecol Oncol. 2015 Apr 22. pii: S0090-8258(15)00830.
    PubMed     Text format     Abstract available


  285. JANCO JM, Glaser G, Kim B, McGree ME, et al
    Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2015 Apr 22. pii: S0090-8258(15)00832.
    PubMed     Text format     Abstract available


  286. MIYASAKA A, Oda K, Ikeda Y, Sone K, et al
    PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer.
    Gynecol Oncol. 2015 Apr 22. pii: S0090-8258(15)00835.
    PubMed     Text format     Abstract available


  287. HIRTE H, Lheureux S, Fleming GF, Sugimoto A, et al
    A Phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A Trial of the Princess Margaret, Chicago and California Phase II Consortia.
    Gynecol Oncol. 2015 Apr 17. pii: S0090-8258(15)00828.
    PubMed     Text format     Abstract available


  288. TOUHAMI O, Trinh XB, Gregoire J, Sebastianelli A, et al
    Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer.
    Gynecol Oncol. 2015 Apr 17. pii: S0090-8258(15)00827.
    PubMed     Text format     Abstract available


  289. FOX E, McCuaig J, Demsky R, Shuman C, et al
    The sooner the better: Genetic testing following ovarian cancer diagnosis.
    Gynecol Oncol. 2015 Apr 11. pii: S0090-8258(15)00788.
    PubMed     Text format     Abstract available


  290. SUH DH, Park JY, Lee JY, Kim BG, et al
    The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
    Gynecol Oncol. 2015 Apr 11. pii: S0090-8258(15)00789.
    PubMed     Text format     Abstract available


  291. FORDE GK, Chang J, Ziogas A, Tewari K, et al
    Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
    Gynecol Oncol. 2015 Apr 10. pii: S0090-8258(15)00778.
    PubMed     Text format     Abstract available


  292. LIAO JB, Yip YY, Swisher EM, Agnew K, et al
    Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.
    Gynecol Oncol. 2015 Apr 9. pii: S0090-8258(15)00772.
    PubMed     Text format     Abstract available


  293. EDQVIST PH, Huvila J, Forsstrom B, Talve L, et al
    Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2015 Apr 7. pii: S0090-8258(15)00783.
    PubMed     Text format     Abstract available


  294. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
    Gynecol Oncol. 2015 Apr 1. pii: S0090-8258(15)00782.
    PubMed     Text format     Abstract available


    March 2015
  295. JOSEPH N, Clark RM, Dizon DS, Lee MS, et al
    Delay in Chemotherapy Administration Impacts Survival in Elderly Patients with Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 Mar 31. pii: S0090-8258(15)00780.
    PubMed     Text format     Abstract available


  296. BUTLER J, Gildea C, Poole J, Meechan D, et al
    Specialist Surgery for Ovarian Cancer in England.
    Gynecol Oncol. 2015 Mar 31. pii: S0090-8258(15)00678.
    PubMed     Text format     Abstract available


  297. BAKER J, Janda M, Graves N, Bauer J, et al
    Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial.
    Gynecol Oncol. 2015 Mar 28. pii: S0090-8258(15)00776.
    PubMed     Text format     Abstract available


  298. GOMEZ-HIDALGO NR, Martinez-Cannon BA, Nick AM, Lu KH, et al
    Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care.
    Gynecol Oncol. 2015 Mar 28. pii: S0090-8258(15)00777.
    PubMed     Text format     Abstract available


  299. BENEDETTI PANICI P, Di Donato V, Fischetti M, Casorelli A, et al
    Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.
    Gynecol Oncol. 2015 Mar 27. pii: S0090-8258(15)00771.
    PubMed     Text format     Abstract available


  300. COLEMAN RL, Sill MW, Bell-McGuinn K, Aghajanian C, et al
    A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An N
    Gynecol Oncol. 2015 Mar 24. pii: S0090-8258(15)00759.
    PubMed     Text format     Abstract available


  301. CANNIOTO RA, Moysich KB
    Epithelial Ovarian Cancer and Recreational Physical Activity: A Review of the Epidemiological Literature and Implications for Exercise Prescription.
    Gynecol Oncol. 2015 Mar 19. pii: S0090-8258(15)00733.
    PubMed     Text format     Abstract available


  302. ROQUE DM, Ratner ES, Silasi DA, Azodi M, et al
    Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Gynecol Oncol. 2015 Mar 17. pii: S0090-8258(15)00683.
    PubMed     Text format     Abstract available


  303. GEELS YP, van der Putten LJ, van Tilborg AA, Lurkin I, et al
    Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Gynecol Oncol. 2015 Mar 12. pii: S0090-8258(15)00682.
    PubMed     Text format     Abstract available


  304. DIAZ-PADILLA I, Wilson MK, Clarke BA, Hirte HW, et al
    A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret Cancer Centre, Chicago and California phase II consor
    Gynecol Oncol. 2015 Mar 11. pii: S0090-8258(15)00680.
    PubMed     Text format     Abstract available


  305. PEARL ML, Dong H, Tulley S, Zhao Q, et al
    Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
    Gynecol Oncol. 2015 Mar 11. pii: S0090-8258(15)00677.
    PubMed     Text format     Abstract available


  306. MEISEL JL, Hyman DM, Jotwani A, Zhou Q, et al
    The role of systemic chemotherapy in the management of granulosa cell tumors.
    Gynecol Oncol. 2015;136:505-11.
    PubMed     Text format     Abstract available


    February 2015
  307. MA R, Ye X, Cheng H, Ma Y, et al
    PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2015 Feb 28. pii: S0090-8258(15)00667.
    PubMed     Text format     Abstract available


  308. WEFERS C, Lambert LJ, Torensma R, Hato SV, et al
    Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
    Gynecol Oncol. 2015 Feb 26. pii: S0090-8258(15)00659.
    PubMed     Text format     Abstract available


  309. WALSH CS
    Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
    Gynecol Oncol. 2015 Feb 25. pii: S0090-8258(15)00657.
    PubMed     Text format     Abstract available


  310. DINKELSPIEL HE, Tergas AI, Zimmerman LA, Burke WM, et al
    Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
    Gynecol Oncol. 2015 Feb 20. pii: S0090-8258(15)00653.
    PubMed     Text format     Abstract available


  311. TEMPFER CB, Winnekendonk G, Solass W, Horvat R, et al
    Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.
    Gynecol Oncol. 2015 Feb 18. pii: S0090-8258(15)00649.
    PubMed     Text format     Abstract available


  312. MARCHIO C, De Filippo MR, Ng CK, Piscuoglio S, et al
    PIKing the type and pattern of PI3K pathway mutations in endometrial endometrioid carcinomas.
    Gynecol Oncol. 2015 Feb 18. pii: S0090-8258(15)00650.
    PubMed     Text format     Abstract available


  313. KATO K, Usami T, Takeshima N
    Secondary debulking surgery for isolated para-aortic nodal recurrence in ovarian cancer involving the division of the left renal vein.
    Gynecol Oncol. 2015 Feb 11. pii: S0090-8258(15)00612.
    PubMed     Text format     Abstract available


  314. MABUCHI S, Kuroda H, Takahashi R, Sasano T, et al
    The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Gynecol Oncol. 2015 Feb 9. pii: S0090-8258(15)00606.
    PubMed     Text format     Abstract available


  315. VAN DE LAAR R, Massuger LF, Van Gorp T, IntHout J, et al
    External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2015 Feb 9. pii: S0090-8258(15)00607.
    PubMed     Text format     Abstract available


  316. YANG X, Feng Y, Gao Y, Shen J, et al
    NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Gynecol Oncol. 2015 Feb 9. pii: S0090-8258(15)00605.
    PubMed     Text format     Abstract available


  317. LU SM, Chang-Halpenny C, Hwang-Graziano J
    Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
    Gynecol Oncol. 2015 Feb 7. pii: S0090-8258(15)00589.
    PubMed     Text format     Abstract available


  318. ARTS-DE JONG M, Harmsen MG, Hoogerbrugge N, Massuger LF, et al
    Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
    Gynecol Oncol. 2015;136:305-10.
    PubMed     Text format     Abstract available


  319. EDDIE SL, Quartuccio SM, Zhu J, Shepherd JA, et al
    Three-dimensional modeling of the human fallopian tube fimbriae.
    Gynecol Oncol. 2015;136:348-54.
    PubMed     Text format     Abstract available


  320. YANG YI, Ahn JH, Choi YS, Choi JH, et al
    Brown algae phlorotannins enhance the tumoricidal effect of cisplatin and ameliorate cisplatin nephrotoxicity.
    Gynecol Oncol. 2015;136:355-64.
    PubMed     Text format     Abstract available


    January 2015
  321. MEYER LA, Nick AM, Shi Q, Wang XS, et al
    Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients.
    Gynecol Oncol. 2015 Jan 31. pii: S0090-8258(15)00590.
    PubMed     Text format     Abstract available


  322. MINION LE, Dolinsky JS, Chase DM, Dunlop CL, et al
    Hereditary Predisposition to Ovarian Cancer, Looking Beyond BRCA1/BRCA2.
    Gynecol Oncol. 2015 Jan 23. pii: S0090-8258(15)00541.
    PubMed     Text format     Abstract available


  323. HENDRICKSON AW, Hawthorne KM, Goode EL, Kalli KR, et al
    Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
    Gynecol Oncol. 2015 Jan 22. pii: S0090-8258(15)00582.
    PubMed     Text format     Abstract available


  324. SORENSEN RD, Schnack TH, Karlsen MA, Hogdall CK, et al
    Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review.
    Gynecol Oncol. 2015 Jan 20. pii: S0090-8258(15)00538.
    PubMed     Text format     Abstract available


  325. GROWDON WB, Groeneweg J, Byron V, DiGloria C, et al
    HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Gynecol Oncol. 2015 Jan 17. pii: S0090-8258(15)00537.
    PubMed     Text format     Abstract available


  326. LI J, Li L, Li Z, Gong G, et al
    The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion.
    Gynecol Oncol. 2015 Jan 15. pii: S0090-8258(15)00535.
    PubMed     Text format     Abstract available


  327. PINK RC, Samuel P, Massa D, Caley DP, et al
    The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Gynecol Oncol. 2015 Jan 8. pii: S0090-8258(15)00004.
    PubMed     Text format     Abstract available


  328. HEFLER-FRISCHMUTH K, Lafleur J, Hefler L, Polterauer S, et al
    Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
    Gynecol Oncol. 2015 Jan 7. pii: S0090-8258(15)00003.
    PubMed     Text format     Abstract available


  329. STIEKEMA A, Boldingh QJ, Korse CM, van der Noort V, et al
    Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Gynecol Oncol. 2015 Jan 2. pii: S0090-8258(14)01635.
    PubMed     Text format     Abstract available


  330. GUNDERSON CC, Moore KN
    PARP Inhibition in Ovarian Cancer: State of the Science.
    Gynecol Oncol. 2015;136:8-10.
    PubMed     Text format    


  331. GOFF B
    Measuring ovarian cancer care: why are we still failing?
    Gynecol Oncol. 2015;136:1-2.
    PubMed     Text format    


  332. FLOQUET A, Vergote I, Colombo N, Fiane B, et al
    Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
    Gynecol Oncol. 2015;136:37-42.
    PubMed     Text format     Abstract available


    December 2014
  333. KIM C, Jeong SY, Chong GO, Son SH, et al
    Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Gynecol Oncol. 2014 Dec 31. pii: S0090-8258(14)01630.
    PubMed     Text format     Abstract available


  334. PRAHM KP, Karlsen MA, Hogdall E, Scheller NM, et al
    The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics.
    Gynecol Oncol. 2014 Dec 26. pii: S0090-8258(14)01626.
    PubMed     Text format     Abstract available


  335. MIZUNO T, Suzuki N, Makino H, Furui T, et al
    Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.
    Gynecol Oncol. 2014 Dec 23. pii: S0090-8258(14)01560.
    PubMed     Text format     Abstract available


  336. CHASE DM, Huang H, Foss CD, Wenzel LB, et al
    Neurotoxicity in Ovarian Cancer Patients on Gynecologic Oncology Group (GOG) Protocol 218: Characteristics Associated with Toxicity and the Effect of Substitution with Docetaxel: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2014 Dec 18. pii: S0090-8258(14)01576.
    PubMed     Text format     Abstract available


  337. LEE AW, Tyrer JP, Doherty JA, Stram DA, et al
    Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.
    Gynecol Oncol. 2014 Dec 17. pii: S0090-8258(14)01572.
    PubMed     Text format     Abstract available


  338. SEIDMAN JD, Vang R, Ronnett BM, Yemelyanova A, et al
    Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification.
    Gynecol Oncol. 2014 Dec 17. pii: S0090-8258(14)01573.
    PubMed     Text format     Abstract available


  339. OTTOLINA J, Ferrandina G, Gadducci A, Scollo P, et al
    Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?
    Gynecol Oncol. 2014 Dec 17. pii: S0090-8258(14)01571.
    PubMed     Text format     Abstract available


  340. SOLHEIM O, Trope CG, Rokkones E, Kaern J, et al
    Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
    Gynecol Oncol. 2014 Dec 12. pii: S0090-8258(14)01565.
    PubMed     Text format     Abstract available


  341. ELSHAIKH MA, Al-Wahab Z, Mahdi H, Albuquerque K, et al
    Recurrence Patterns and Survival Endpoints in Women with Stage II Uterine Endometrioid Carcinoma: A Multi-institution Study.
    Gynecol Oncol. 2014 Dec 12. pii: S0090-8258(14)01567.
    PubMed     Text format     Abstract available


  342. OMAR T, Marie P
    Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: A review.
    Gynecol Oncol. 2014 Dec 12. pii: S0090-8258(14)01566.
    PubMed     Text format     Abstract available


  343. TRAN CW, McGree ME, Weaver AL, Martin JR, et al
    Surgical site infection after primary surgery for epithelial ovarian cancer: predictors and impact on survival.
    Gynecol Oncol. 2014 Dec 10. pii: S0090-8258(14)01562.
    PubMed     Text format     Abstract available


  344. MATSUO K, Yoshino K, Hasegawa K, Murakami R, et al
    Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
    Gynecol Oncol. 2014 Dec 10. pii: S0090-8258(14)01561.
    PubMed     Text format     Abstract available


  345. JENSEN SE, Kaiser K, Lacson L, Schink J, et al
    Content validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
    Gynecol Oncol. 2014 Dec 8. pii: S0090-8258(14)01555.
    PubMed     Text format     Abstract available


  346. GROEN RS, Gershenson DM, Fader AN
    Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all.
    Gynecol Oncol. 2014 Dec 3. pii: S0090-8258(14)01551.
    PubMed     Text format     Abstract available


  347. ETEMADMOGHADAM D, Bowtell D
    AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: Mounting evidence of a therapeutic target.
    Gynecol Oncol. 2014;135:409-10.
    PubMed     Text format    


    November 2014
  348. CHIVA LM, Gonzalez-Martin A
    A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
    Gynecol Oncol. 2014 Nov 27. pii: S0090-8258(14)01537.
    PubMed     Text format     Abstract available


  349. PLAMADEALA V, Kelley JL, Chan JK, Krivak TC, et al
    A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2014 Nov 25. pii: S0090-8258(14)01484.
    PubMed     Text format     Abstract available


  350. HONG SH, Lee S, Kim HG, Lee HJ, et al
    Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_ KCSG GY10-10.
    Gynecol Oncol. 2014 Nov 22. pii: S0090-8258(14)01482.
    PubMed     Text format     Abstract available


  351. GOTTSCHAU M, Kjaer SK, Jensen A, Munk C, et al
    Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study.
    Gynecol Oncol. 2014 Nov 20. pii: S0090-8258(14)01475.
    PubMed     Text format     Abstract available


  352. SHIM SH, Lee SJ, Kim SO, Kim SN, et al
    Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
    Gynecol Oncol. 2014 Nov 9. pii: S0090-8258(14)01417.
    PubMed     Text format     Abstract available


  353. CRANE EK, Sun CC, Ramirez PT, Schmeler KM, et al
    The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
    Gynecol Oncol. 2014 Nov 8. pii: S0090-8258(14)01418.
    PubMed     Text format     Abstract available


  354. TEW WP, Fleming GF
    Treatment of ovarian cancer in the older woman.
    Gynecol Oncol. 2014 Nov 3. pii: S0090-8258(14)01412.
    PubMed     Text format     Abstract available


  355. BONNEAU C, Rouzier R, Geyl C, Cortez A, et al
    Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Gynecol Oncol. 2014 Nov 1. pii: S0090-8258(14)01408.
    PubMed     Text format     Abstract available


    October 2014
  356. MATSUMOTO K, Katsumata N, Shibata T, Satoh T, et al
    Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
    Gynecol Oncol. 2014 Oct 31. pii: S0090-8258(14)01410.
    PubMed     Text format     Abstract available


  357. CLIBY WA, Powell MA, Al-Hammadi N, Chen L, et al
    Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival.
    Gynecol Oncol. 2014 Oct 29. pii: S0090-8258(14)01407.
    PubMed     Text format     Abstract available


  358. TATE THIGPEN J
    Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
    Gynecol Oncol. 2014 Oct 24. pii: S0090-8258(14)01370.
    PubMed     Text format     Abstract available


  359. MOORE RG, Hawkins DM, Miller MC, Landrum LM, et al
    Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer.
    Gynecol Oncol. 2014 Oct 23. pii: S0090-8258(14)01401.
    PubMed     Text format     Abstract available


  360. COHN DE, Barnett JC, Wenzel L, Monk BJ, et al
    A cost-utility analysis of an NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected Quality-of-life scores in an economic model of treatment of ovarian cancer.
    Gynecol Oncol. 2014 Oct 23. pii: S0090-8258(14)01404.
    PubMed     Text format     Abstract available


  361. BUTLER-MANUEL S, Lippiatt J, Madhuri TK
    Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet).
    Gynecol Oncol. 2014 Oct 22. pii: S0090-8258(14)01310.
    PubMed     Text format     Abstract available


  362. FUH KC, Shin JY, Kapp DS, Brooks RA, et al
    Survival Differences of Asian and Caucasian Epithelial Ovarian Cancer Patients in the United States.
    Gynecol Oncol. 2014 Oct 16. pii: S0090-8258(14)01369.
    PubMed     Text format     Abstract available


  363. LESSARD-ANDERSON CR, Handlogten KS, Molitor RJ, Dowdy SC, et al
    Effect of Tubal Sterilization Technique on Risk of Serous Ovarian and Primary Peritoneal Carcinoma.
    Gynecol Oncol. 2014 Oct 11. pii: S0090-8258(14)01365.
    PubMed     Text format     Abstract available


  364. PARTRIDGE EE, Spencer EB
    Assessing the risk of ovarian malignancy in asymptomatic women with abnormal findings: "Tilting at windmills".
    Gynecol Oncol. 2014;135:1-2.
    PubMed     Text format    


    September 2014
  365. TEPLINSKY E, Muggia F
    Targeting HER2 in ovarian and uterine cancers: Challenges and future directions.
    Gynecol Oncol. 2014 Sep 13. pii: S0090-8258(14)01306.
    PubMed     Text format     Abstract available


  366. VARGO JA, Boisen MM, Comerci JT, Kim H, et al
    Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
    Gynecol Oncol. 2014 Sep 9. pii: S0090-8258(14)01304.
    PubMed     Text format     Abstract available


  367. BOYLE J, Craciunescu O, Steffey B, Cai J, et al
    Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
    Gynecol Oncol. 2014 Sep 2. pii: S0090-8258(14)01300.
    PubMed     Text format     Abstract available


    August 2014
  368. DESAI PH, Hughes P, Tobias DH, Tchabo N, et al
    Accuracy of robotic sentinel lymph node detection (RSLND) for patients with endometrial cancer (EC).
    Gynecol Oncol. 2014 Aug 28. pii: S0090-8258(14)01285.
    PubMed     Text format     Abstract available


  369. TSOREF D, Welch S, Lau S, Biagi J, et al
    Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Gynecol Oncol. 2014 Aug 28. pii: S0090-8258(14)01074.
    PubMed     Text format     Abstract available


  370. SCHNACK TH, Sorensen RD, Nedergaard L, Hogdall C, et al
    Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology - A prospective comparative study.
    Gynecol Oncol. 2014 Aug 26. pii: S0090-8258(14)01273.
    PubMed     Text format     Abstract available


  371. HUSSEINZADEH N, Davenport SM
    Role of Toll-Like Receptors in cervical, endometrial and ovarian cancers: A Review.
    Gynecol Oncol. 2014 Aug 15. pii: S0090-8258(14)01266.
    PubMed     Text format     Abstract available


  372. SLIPICEVIC A, Holth A, Hellesylt E, Trope CG, et al
    Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
    Gynecol Oncol. 2014 Aug 2. pii: S0090-8258(14)01225.
    PubMed     Text format     Abstract available


  373. VIERKOETTER KR, Ayabe AR, VanDrunen M, Ahn HJ, et al
    Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.
    Gynecol Oncol. 2014 Aug 2. pii: S0090-8258(14)01223.
    PubMed     Text format     Abstract available


  374. WORLEY MJ JR, Davis M, Berhie SH, Muto MG, et al
    Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
    Gynecol Oncol. 2014 Aug 1. pii: S0090-8258(14)01221.
    PubMed     Text format     Abstract available


    July 2014
  375. ELDER JW, Pavlik EJ, Long A, Miller RW, et al
    Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index.
    Gynecol Oncol. 2014 Jul 25. pii: S0090-8258(14)01209.
    PubMed     Text format     Abstract available


  376. KOC N, Ayas S, Uygur L
    The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.
    Gynecol Oncol. 2014 Jul 17. pii: S0090-8258(14)01207.
    PubMed     Text format     Abstract available


  377. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A Multicenter Prospective Trial Evaluating the Ability of Preoperative Computed Tomography Scan and Serum CA-125 to Predict Suboptimal Cytoreduction at Primary Debulking Surgery for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer.
    Gynecol Oncol. 2014 Jul 11. pii: S0090-8258(14)01077.
    PubMed     Text format     Abstract available


  378. PENSON RT, Moore KM, Fleming GF, Braly P, et al
    A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2014 Jul 10. pii: S0090-8258(14)01070.
    PubMed     Text format     Abstract available


  379. NAGEL CI, Thomas SK, Richardson DL, Kehoe SM, et al
    Adnexal masses requiring surgical intervention in women with advanced cervical cancer.
    Gynecol Oncol. 2014 Jul 9. pii: S0090-8258(14)01073.
    PubMed     Text format     Abstract available


  380. CHEN HF, Chang YH, Ko MC, Li CY, et al
    A large scale population-based cohort study on the risk of ovarian neoplasm in patients with type 2 diabetes mellitus.
    Gynecol Oncol. 2014 Jul 9. pii: S0090-8258(14)01076.
    PubMed     Text format     Abstract available


  381. PARK YA, Choi CH, Do IG, Song SY, et al
    Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma.
    Gynecol Oncol. 2014 Jul 9. pii: S0090-8258(14)01072.
    PubMed     Text format     Abstract available


  382. FAN L, Chen J, Zhang X, Liu Y, et al
    Follicle-stimulating hormone polypeptide in treatment of lymphatic metastasis during ovarian carcinoma therapy via nanopariticle drug delivery system.
    Gynecol Oncol. 2014 Jul 5. pii: S0090-8258(14)01071.
    PubMed     Text format     Abstract available


  383. COHEN S, Mosig R, Moshier E, Pereira E, et al
    Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2014 Jul 1. pii: S0090-8258(14)01066.
    PubMed     Text format     Abstract available


    June 2014
  384. JUTZI L, Russell D, Ho S, Kwon JS, et al
    The role of palliative colorectal stents in gynecologic malignancy.
    Gynecol Oncol. 2014 Jun 28. pii: S0090-8258(14)01061.
    PubMed     Text format     Abstract available


  385. VAN MEURS HS, Schuit E, Horlings HM, van der Velden J, et al
    Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary.
    Gynecol Oncol. 2014 Jun 28. pii: S0090-8258(14)01062.
    PubMed     Text format     Abstract available


  386. LAWRENSON K, Lee N, Torres HA, Lee JM, et al
    Src as a Novel Therapeutic Target for Endometriosis.
    Gynecol Oncol. 2014 Jun 24. pii: S0090-8258(14)01056.
    PubMed     Text format     Abstract available


  387. GLASGOW MA, Shields K, Vogel RI, Teoh D, et al
    Postoperative Readmissions following Ileostomy Formation among Patients with a Gynecologic Malignancy.
    Gynecol Oncol. 2014 Jun 13. pii: S0090-8258(14)01036.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: